Abstract:Antisense oligodeoxynucleotide (ASODN) can directly interfere a series of biological events of the target RNA derived from tumor cells through Watson-Crick base pairing, in turn, plays antitumor therapeutic roles. In the study, a novel HIF-1 a ASODN-loaded nanocomposite was formulated to efficiently deliver gene to the target RNA. The physicochemical properties of nanocomposite were characterized using TEM, FTIR, DLS and zeta potentials. The mean diameter of resulting GEL-DGL-FA-ASODN-DCA nanocomposite was about 170-192 nm, and according to the agarose gel retardation assay, the loading amount of ASODN accounted for 166.7 mg/g. The results of cellular uptake showed that the nanocomposite could specifically target to HepG2 and Hela cells. The cytotoxicity assay demonstrated that the toxicity of vectors was greatly reduced by using DCA to reversibly block the cationic DGL. The subcellular distribution images clearly displayed the lysosomal escape ability of the DCA-modified nanocomposite. In vitro exploration of molecular mechanism indicated that the nanocomposite could inhibit mRNA expression and HIF-1 a protein translation at different levels. In vivo optical images and quantitative assay testified that the formulation accumulated preferentially in the tumor tissue. In vivo antitumor efficacy research confirmed that this nanocomposite had significant antitumor activity and the tumor inhibitory rate was 77.99%. These results manifested that the GEL-DGL-FA-ASODN-DCA nanocomposite was promising in gene therapeutics for antitumor by interacting directly with target RNA. Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Enhanced antisense oligonucleotide delivery using cationic liposomes incorporating fatty acid-modified polyethylenimine.

A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery

Modified ASO Conjugates Encapsulated with Cytidinyl/cationic Lipids Exhibit More Potent and Longer-Lasting Anti-Hcc Effects

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

Enhanced Sirna Delivery Using Oleic Acid Derivative of Polyethylenimine

Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection

Enhanced lysosome escape mediated by 1,2-dicarboxylic-cyclohexene anhydride-modified poly-L-lysine dendrimer as a gene delivery system

A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides

Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide Against HIF-1α.

Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy

Copolymer of Poly(Ethylene Glycol) and Poly((L)-Lysine) Grafting Polyethylenimine Through A Reducible Disulfide Linkage for Sirna Delivery

High-Resolution Visualisation of Antisense Oligonucleotide Release from Polymers in Cells

Telomerase-targeting antisense oligonucleotides carried by polycation liposomes enhance the growth inhibition effect on tumor cells.

Studies on Cationic Polycarylate Liposome Composite Microparticles As Vehicle of Antisene Oligodeoxynucleotides

Fatty acid modified octa-arginine for delivery of siRNA

Targeted Delivery of Antisense Oligodeoxynucleotides to Folate Receptor-Overexpressing Tumor Cells

Alkane-modified low-molecular-weight polyethylenimine with enhanced gene silencing for siRNA delivery.

Toxicological Exploration of Peptide-Based Cationic Liposomes in Sirna Delivery.

Self‐Assembled Antibody‐Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides